Essential considerations for using protein-ligand structures in drug discovery.

scientific article published on 21 June 2012

Essential considerations for using protein-ligand structures in drug discovery. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.DRUDIS.2012.06.011
P698PubMed publication ID22728777
P5875ResearchGate publication ID228062835

P50authorThanh D DoQ56152984
Anthony NichollsQ4773189
P2093author name stringBrian P Kelley
Stephen D Warren
Gregory L Warren
P433issue23-24
P921main subjectdrug discoveryQ1418791
P304page(s)1270-1281
P577publication date2012-06-21
P1433published inDrug Discovery TodayQ3040085
P1476titleEssential considerations for using protein-ligand structures in drug discovery
P478volume17

Reverse relations

cites work (P2860)
Q64168599A Diverse Benchmark Based on 3D Matched Molecular Pairs for Validating Scoring Functions
Q28541718A structure-based model for predicting serum albumin binding
Q35201046An integrated approach to knowledge-driven structure-based virtual screening
Q54275024An integrated suite of modeling tools that empower scientists in structure- and property-based drug design.
Q41940007Automating crystallographic structure solution and refinement of protein-ligand complexes.
Q125738545Best Practices for Alchemical Free Energy Calculations [Article v1.0]
Q42119055CREDO: a structural interactomics database for drug discovery
Q30543685CSAR Benchmark Exercise 2011–2012: Evaluation of Results from Docking and Relative Ranking of Blinded Congeneric Series
Q30619853CSAR data set release 2012: ligands, affinities, complexes, and docking decoys
Q90407504Comprehensive Assessment of Torsional Strain in Crystal Structures of Small Molecules and Protein-Ligand Complexes using ab Initio Calculations
Q39138265Computer-aided drug design to explore cyclodextrin therapeutics and biomedical applications.
Q47611051Conformational Aspects in the Design of Inhibitors for Serine Hydroxymethyltransferase (SHMT): Biphenyl, Aryl Sulfonamide, and Aryl Sulfone Motifs.
Q57984891Conformational investigation of the structure-activity relationship of GdFFD and its analogues on an achatin-like neuropeptide receptor of Aplysia californica involved in the feeding circuit
Q46289927Crystal structure of type II NADH:quinone oxidoreductase from Caldalkalibacillus thermarum with an improved resolution of 2.15 Å.
Q36152480Detecting the native ligand orientation by interfacial rigidity: SiteInterlock
Q39317819Docking-undocking combination applied to the D3R Grand Challenge 2015.
Q92610924Experimental and Computational Evaluation of Piperonylic Acid Derived Hydrazones Bearing Isatin Moieties as Dual Inhibitors of Cholinesterases and Monoamine Oxidases
Q39027957Exploring the stability of ligand binding modes to proteins by molecular dynamics simulations
Q93080641Finding High-Quality Metal Ion-Centric Regions Across the Worldwide Protein Data Bank
Q57204523Homology-based loop modeling yields more complete crystallographic protein structures
Q54327473How Diverse Are the Protein-Bound Conformations of Small-Molecule Drugs and Cofactors?
Q64092935ImmtorLig_DB: repertoire of virtually screened small molecules against immune receptors to bolster host immunity
Q28831160Improved ligand geometries in crystallographic refinement using AFITT in PHENIX
Q36329335Improving the accuracy of high-throughput protein-protein affinity prediction may require better training data
Q28829862Kinetic barriers in the isomerization of substituted ureas: implications for computer-aided drug design
Q34657185Learning from our mistakes: The ‘unknown knowns’ in fragment screening
Q30971961Low-Quality Structural and Interaction Data Improves Binding Affinity Prediction via Random Forest.
Q30371590Models of protein-ligand crystal structures: trust, but verify
Q39038055Molecular dynamics simulations reveal structural insights into inhibitor binding modes and functionality in human Group IIA phospholipase A2.
Q36099648Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization
Q30277026Outcome of the First wwPDB/CCDC/D3R Ligand Validation Workshop
Q53185669Predicting the relative binding affinity of mineralocorticoid receptor antagonists by density functional methods
Q50051009Protein-ligand interfaces are polarized: discovery of a strong trend for intermolecular hydrogen bonds to favor donors on the protein side with implications for predicting and designing ligand complexes.
Q36092094Quality Issues with Public Domain Chemogenomics Data.
Q28534778SWEETLEAD: an in silico database of approved drugs, regulated chemicals, and herbal isolates for computer-aided drug discovery
Q35009886Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor α and β subtypes: a molecular modeling study
Q36267055Structure-Based Virtual Screening
Q92635049Structure-Based Virtual Screening, Molecular Dynamics and Binding Free Energy Calculations of Hit Candidates as ALK-5 Inhibitors
Q55669302Superior Performance of the SQM/COSMO Scoring Functions in Native Pose Recognition of Diverse Protein–Ligand Complexes in Cognate Docking.
Q46014526The application of statistical methods to cognate docking: A path forward?
Q42538022The good, the bad and the dubious: VHELIBS, a validation helper for ligands and binding sites
Q86433361Towards predictive docking at aminergic G-protein coupled receptors
Q55059617Validation of ligands in macromolecular structures determined by X-ray crystallography
Q36015308Vinardo: A Scoring Function Based on Autodock Vina Improves Scoring, Docking, and Virtual Screening
Q93239299qFit-ligand Reveals Widespread Conformational Heterogeneity of Drug-Like Molecules in X-Ray Electron Density Maps

Search more.